National class action launched regarding Meridia drug due to Cardiac and
Heart Attack Risks

CALGARY, Oct. 13 /CNW/ - "Our Statement of Claim asserts that one of Canada's most commonly prescribed anti-obesity drugs substantially increases a person's risk of a heart attack", said Tony Merchant, Q.C. Merchant Law Group is launching class action lawsuits in Canada on behalf of all former Canadian users of Meridia (Sibutramine), a prescription drug made by Abbott Laboratories, commonly prescribed to treat obesity. Generic versions of Meridia were also marketed in Canada as Apo-Sibutramine and Novo-Sibutramine.

"Merchant Law Group has already been contacted by former Meridia users from Québec, Ontario, and Alberta, many of whom have suffered serious side effects as a result of using Meridia. Our firm has launched nationwide class action litigation with the courts as a result." said Tony Merchant, Q.C.

Meridia was pulled off the market by its manufacturer last week, in response to an independent study published last month in the prestigious New England Journal of Medicine which found that Meridia puts patients at substantial increased risk of heart attacks. The Meridia class action lawsuits include a class action filed with the court in Montréal on October 12 and a class action to be filed with the court in Toronto on October 13.

Merchant Law Group LLP is a nationally prominent firm in many areas of the law including class actions, with offices in Montreal, Toronto, St. Catharines, Ottawa, Winnipeg, Regina, Saskatoon, Moose Jaw, Edmonton, Calgary, Fort McMurray, Vancouver, and Victoria.

For further information:

http://www.merchantlaw.com/classactions/meridia.php
E. F. Anthony Merchant, Q.C.
306-539-7777 Cellular
[email protected]
or Aroosha Sadaghianloo
416-828-7777 Toronto Office
http://www.merchantlaw.com